Moody Aldrich Partners LLC cut its position in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 60.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,683 shares of the company's stock after selling 16,122 shares during the period. Moody Aldrich Partners LLC's holdings in Arcellx were worth $819,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of ACLX. KBC Group NV raised its position in shares of Arcellx by 37.3% in the fourth quarter. KBC Group NV now owns 1,388 shares of the company's stock valued at $106,000 after purchasing an additional 377 shares during the period. Avanza Fonder AB bought a new stake in Arcellx during the fourth quarter worth about $184,000. Lord Abbett & CO. LLC grew its stake in Arcellx by 2.1% during the third quarter. Lord Abbett & CO. LLC now owns 891,848 shares of the company's stock worth $74,478,000 after buying an additional 18,004 shares in the last quarter. Geode Capital Management LLC increased its holdings in Arcellx by 4.3% in the 3rd quarter. Geode Capital Management LLC now owns 974,967 shares of the company's stock valued at $81,434,000 after buying an additional 39,781 shares during the period. Finally, Wellington Management Group LLP raised its position in shares of Arcellx by 15.2% in the 3rd quarter. Wellington Management Group LLP now owns 20,968 shares of the company's stock valued at $1,751,000 after buying an additional 2,768 shares in the last quarter. Institutional investors own 96.03% of the company's stock.
Insider Transactions at Arcellx
In other news, Director Kavita Patel sold 33,763 shares of the company's stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $104.14, for a total transaction of $3,516,078.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Christopher Heery sold 3,553 shares of the firm's stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $73.69, for a total value of $261,820.57. Following the completion of the sale, the insider now directly owns 25,085 shares of the company's stock, valued at $1,848,513.65. The trade was a 12.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 63,416 shares of company stock valued at $6,242,800 in the last quarter. Insiders own 6.24% of the company's stock.
Wall Street Analyst Weigh In
Several analysts recently issued reports on ACLX shares. Morgan Stanley increased their price target on shares of Arcellx from $81.00 to $106.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 6th. Stifel Nicolaus lifted their price target on Arcellx from $83.00 to $122.00 and gave the company a "buy" rating in a research note on Friday, October 18th. Barclays upgraded Arcellx to a "strong-buy" rating in a research report on Friday, November 29th. Canaccord Genuity Group boosted their target price on Arcellx from $85.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, October 17th. Finally, HC Wainwright restated a "buy" rating and issued a $115.00 price target on shares of Arcellx in a research note on Tuesday, December 10th. Thirteen research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $105.93.
Get Our Latest Analysis on ACLX
Arcellx Trading Up 4.6 %
Shares of ACLX traded up $2.95 during trading hours on Thursday, reaching $67.53. 547,657 shares of the stock traded hands, compared to its average volume of 700,771. Arcellx, Inc. has a 52 week low of $47.88 and a 52 week high of $107.37. The company has a market cap of $3.65 billion, a price-to-earnings ratio of -95.11 and a beta of 0.33. The stock has a fifty day simple moving average of $77.48 and a 200 day simple moving average of $76.72.
Arcellx (NASDAQ:ACLX - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.06. The business had revenue of $26.03 million for the quarter, compared to the consensus estimate of $35.21 million. Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. Analysts predict that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.
Arcellx Profile
(
Free Report)
Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
Further Reading
Before you consider Arcellx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcellx wasn't on the list.
While Arcellx currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
